For once, this isn’t hyperbole. Metastatic pancreatic cancer hasn’t had a meaningful new treatment in literally decades - it’s been brutal chemotherapy or slightly less brutal chemotherapy.
The new generation of KRAS inhibitors, of which daraxonrasib is just the first to make it to approval, is genuinely a practice-changing breakthrough.
It won’t cure people with metastatic disease, but it will help a lot live better lives for longer.
Everything is relative. A few more months of life with less pain and more energy to spend it with family surely is a breakthrough for many patients and for the doctors treating them.
For once, this isn’t hyperbole. Metastatic pancreatic cancer hasn’t had a meaningful new treatment in literally decades - it’s been brutal chemotherapy or slightly less brutal chemotherapy.
The new generation of KRAS inhibitors, of which daraxonrasib is just the first to make it to approval, is genuinely a practice-changing breakthrough.
It won’t cure people with metastatic disease, but it will help a lot live better lives for longer.
> For once, this isn’t hyperbole.
Am I missing something?
From other sources:
> Median overall survival: 13.2 months versus about 6.6 to 6.7 months with chemotherapy.
Doubling life expectancy on a form of cancer infamous as a death sentence.
I don't see that as a breakthrough.
Merely counting months does not do much - you'd have to count the quality of these months too.
Everything is relative. A few more months of life with less pain and more energy to spend it with family surely is a breakthrough for many patients and for the doctors treating them.
But where does it imply less pain? Plus, which pain exactly? Chemotherapy also leads to pain. Prolonging treatment can cause more pain then.
I don't see that as a breakthrough.
In case others are wondering, it looks like this is a different story than this recent one:
Pancreatic cancer halted by virus injection in three patients - https://news.ycombinator.com/item?id=50563066 - Nov 2026 (157 comments)